PMID- 11501493
OWN - NLM
STAT- MEDLINE
DCOM- 20010906
LR  - 20190921
IS  - 0023-5679 (Print)
IS  - 0023-5679 (Linking)
VI  - 48
IP  - 2
DP  - 2001
TI  - Quantification of WT1 mRNA by competitive NASBA in AML patients.
PG  - 129-34
AB  - The measurement of Wilms' tumor gene (WT1) mRNA levels by reverse 
      transcriptase-polymerase chain reaction (RT-PCR) is useful in detecting minimal 
      residual disease (MRD) in leukemia patients. In the present study, we quantified 
      the level of WT1 mRNA in the peripheral blood and bone marrow of patients with 
      acute myelocytic leukemia (AML) at initial onset, remission and recurrence by the 
      use of nucleic acid sequence based amplification (NASBA), and then ascertained 
      the clinical usefulness of this method. At initial onset, the level of WT1 mRNA 
      in the peripheral blood was above 10(3) copies/microgram and that in the bone 
      marrow was above 10(4) copies/microgram. The level of WT1 mRNA was decreased in 
      cases where therapy resulted in complete remission, but it was abnormally high in 
      recurring cases. In AML (M3) patients, the relationship between the level of WT1 
      mRNA and the expression of the PML-retinoic acid alpha receptor (RAR alpha) gene, 
      assessed by fluorescence in situ hybridization (FISH), was investigated. When 
      leukemia was in remission hematologically, the PML-RAR alpha gene was negative 
      and the level of WT1 mRNA decreased. These findings suggest that the 
      quantification of WT1 gene expression by competitive NASBA is useful in assessing 
      therapeutic effects and detecting MRD.
FAU - Fukahori, S
AU  - Fukahori S
AD  - Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Kurume Med J
JT  - The Kurume medical journal
JID - 2985210R
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 0 (WT1 Proteins)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/genetics
MH  - Neoplasm, Residual
MH  - Oncogene Proteins, Fusion/genetics
MH  - RNA, Messenger/*analysis
MH  - *Reverse Transcriptase Polymerase Chain Reaction
MH  - Transcription Factors/*genetics
MH  - WT1 Proteins
EDAT- 2001/08/15 10:00
MHDA- 2001/09/08 10:01
CRDT- 2001/08/15 10:00
PHST- 2001/08/15 10:00 [pubmed]
PHST- 2001/09/08 10:01 [medline]
PHST- 2001/08/15 10:00 [entrez]
AID - 10.2739/kurumemedj.48.129 [doi]
PST - ppublish
SO  - Kurume Med J. 2001;48(2):129-34. doi: 10.2739/kurumemedj.48.129.